No financial details given, but completion is expected at the end of this month
Cambridge Major Laboratories (CML), a US developer and manufacturer of active pharmaceutical ingredients has merged with another American firm, AAIPharma Services, a provider of pharmaceutical analytical testing, product development, and manufacturing services.
The firms say the merger will create a premier global supplier of integrated chemistry, manufacturing and control (CMC) services.
Financial terms have not been revealed, although completion is expected by the end of this month (October).
'The basis for the merger was to start with the right building blocks – a merger of two equals: two highly respected, market-leading firms with proven expertise in API development, analytical chemistry, and finished dosage forms,' said Brian Scanlan, CEO and President of CML.
'Joining forces to offer a full suite of integrated CMC services delivers meaningful value to customers and the ability to execute with equal strength across API development, analytical services, and finished dosage form manufacturing.'
Patrick Walsh, CEO of AAIPharma Services, added that the merger will 'offer customers a reliable partner that can address the majority of their pharmaceutical development and manufacturing requirements'.
'The combined organisation will provide comprehensive services that include process chemistry, solid state chemistry, API manufacturing, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid and sterile), packaging, and stability services, all supported by robust project management.'